<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054300</url>
  </required_header>
  <id_info>
    <org_study_id>8835-040</org_study_id>
    <secondary_id>B1521007</secondary_id>
    <secondary_id>MK-8835-040</secondary_id>
    <nct_id>NCT01054300</nct_id>
  </id_info>
  <brief_title>Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using
      2 cohorts. The objective of the study is to evaluate the pharmacodynamics (PD) effects and
      the pharmacokinetic (PK) of single day dosing of 2 mg and 4 mg doses of ertugliflozin (Ertu,
      PF-04971729/MK-8835) each administered once vs twice daily (morning [AM] and evening [PM]) in
      adults with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2010</start_date>
  <completion_date type="Actual">April 7, 2010</completion_date>
  <primary_completion_date type="Actual">April 7, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Urinary Glucose Excretion Over 0 to 24 Hours</measure>
    <time_frame>0 to 24 hours after the morning dose</time_frame>
    <description>Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted from 0 to 24 hours after the morning dose is presented in the table below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Glucose Excretion by Time Period</measure>
    <time_frame>At 0-4 hrs, 4-8 hrs, 8-12 hrs, and 12-24 hrs after the AM dose (up to 24 hours)</time_frame>
    <description>Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted during the pre-specified time frame is presented in the table below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour Weighted Mean Plasma Glucose</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Blood was collected during each treatment period at pre-dose (fasted) on Day 1 (Hour 0) and post-dose (fed) on Day 1 at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 12.5, 13, 14, 15, 16, 18, and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted Mean Postprandial Plasma Glucose</measure>
    <time_frame>At 0-5 hours, 5-12 hrs, and 12-18 hrs after the morning dose (up to 18 hours)</time_frame>
    <description>The weighted mean postprandial glucose over the specified intervals were analyzed by cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Blood samples were to be collected following a fast from all food and drink (except water) for at least 8 hours. Fasting Plasma Glucose was collected as part of the assessment of weighted mean 24-hour plasma glucose. As such, it was not specified as an endpoint in the Statistical Analysis Plan and was not analyzed or summarized separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting C-peptide</measure>
    <time_frame>Up to 24 hours (0 and 24 hours)</time_frame>
    <description>The fasting c-peptide was analyzed by cohort using a mixed-effects model with sequence, period, and treatment as fixed effects and participant within sequence as a random effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 8 days (Day 1 in each dosing period)</time_frame>
    <description>An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug. Data include participants discontinued due to adverse events, participants with dose reduced or temporary discontinuation due to adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin</measure>
    <time_frame>0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose</time_frame>
    <description>Pharmacokinetic (PK) parameter of AUClast for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ertugliflozin</measure>
    <time_frame>0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose</time_frame>
    <description>PK parameter of Cmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin</measure>
    <time_frame>0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose</time_frame>
    <description>PK parameter of Tmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Adult</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 2 mg single dose</intervention_name>
    <description>Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose</description>
    <arm_group_label>Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo</arm_group_label>
    <arm_group_label>Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 2 mg split into twice daily</intervention_name>
    <description>Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day</description>
    <arm_group_label>Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo</arm_group_label>
    <arm_group_label>Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 4 mg single dose</intervention_name>
    <description>Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose</description>
    <arm_group_label>Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo</arm_group_label>
    <arm_group_label>Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 4 mg split into twice daily</intervention_name>
    <description>Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day</description>
    <arm_group_label>Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo</arm_group_label>
    <arm_group_label>Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to ertugliflozin administered as a single dose</description>
    <arm_group_label>Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo</arm_group_label>
    <arm_group_label>Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg</arm_group_label>
    <arm_group_label>Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo</arm_group_label>
    <arm_group_label>Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with type 2 diabetes mellitus, either treatment-naïve or on up to 2
             acceptable oral anti-diabetes drugs for at least 8-weeks prior to study.

        Exclusion Criteria:

          -  Participants with type 1 diabetes mellitus, participants with stroke, unstable angina,
             heart attack in last 6-months, uncontrolled blood pressure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Dawra VK, Liang Y, Shi H, Bass A, Hickman A, Terra SG, Zhou S, Cutler D, Sahasrabudhe V. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects . Int J Clin Pharmacol Ther. 2019 Apr;57(4):207-216. doi: 10.5414/CP203343.</citation>
    <PMID>30802200</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>December 6, 2017</results_first_submitted>
  <results_first_submitted_qc>September 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 7, 2018</results_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Ertu 2 mg/Pbo→Ertu 1 mg/Ertu 1 mg</title>
          <description>Period 1: Ertugliflozin (Ertu) 2 mg in the AM and placebo (Pbo) in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo</title>
          <description>Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg</title>
          <description>Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/P</title>
          <description>Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">Discontinuation occurred prior to Period 2 dose.</participants>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Period 1: participants received a total daily dose of ertugliflozin 2 mg for 1 day; Period 2: participants received a total daily dose of ertugliflozin 2 mg for 1 day</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Period 1: participants received a total daily dose of ertugliflozin 4 mg; Period 2: participants received a total daily dose of ertugliflozin 4 mg for 1 day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years or older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Urinary Glucose Excretion Over 0 to 24 Hours</title>
        <description>Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted from 0 to 24 hours after the morning dose is presented in the table below.</description>
        <time_frame>0 to 24 hours after the morning dose</time_frame>
        <population>Analysis population included randomized participants who received assigned dose and had urine collection during all of the collection time frames between 0 and 24 hours following the morning dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urinary Glucose Excretion Over 0 to 24 Hours</title>
          <description>Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted from 0 to 24 hours after the morning dose is presented in the table below.</description>
          <population>Analysis population included randomized participants who received assigned dose and had urine collection during all of the collection time frames between 0 and 24 hours following the morning dose.</population>
          <units>Grams</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.45" spread="9.08" lower_limit="54.20" upper_limit="84.70"/>
                    <measurement group_id="O2" value="70.43" spread="9.08" lower_limit="55.19" upper_limit="85.68"/>
                    <measurement group_id="O3" value="78.29" spread="9.77" lower_limit="61.87" upper_limit="94.72"/>
                    <measurement group_id="O4" value="80.54" spread="9.81" lower_limit="64.05" upper_limit="97.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Glucose Excretion by Time Period</title>
        <description>Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted during the pre-specified time frame is presented in the table below.</description>
        <time_frame>At 0-4 hrs, 4-8 hrs, 8-12 hrs, and 12-24 hrs after the AM dose (up to 24 hours)</time_frame>
        <population>Analysis population included randomized participants who received assigned dose and had urine collection during the specific time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion by Time Period</title>
          <description>Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted during the pre-specified time frame is presented in the table below.</description>
          <population>Analysis population included randomized participants who received assigned dose and had urine collection during the specific time frame.</population>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 4 hours post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.88" spread="14.66"/>
                    <measurement group_id="O2" value="14.03" spread="11.63"/>
                    <measurement group_id="O3" value="14.66" spread="11.81"/>
                    <measurement group_id="O4" value="16.34" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 to 8 hours post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.42" spread="12.00"/>
                    <measurement group_id="O2" value="17.87" spread="12.60"/>
                    <measurement group_id="O3" value="16.97" spread="11.64"/>
                    <measurement group_id="O4" value="19.78" spread="14.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 to 12 hours post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.47" spread="8.84"/>
                    <measurement group_id="O2" value="11.99" spread="7.70"/>
                    <measurement group_id="O3" value="14.30" spread="10.52"/>
                    <measurement group_id="O4" value="12.91" spread="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to 24 hours post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.76" spread="20.10"/>
                    <measurement group_id="O2" value="26.31" spread="21.11"/>
                    <measurement group_id="O3" value="31.47" spread="22.71"/>
                    <measurement group_id="O4" value="32.94" spread="21.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>24-hour Weighted Mean Plasma Glucose</title>
        <description>Blood was collected during each treatment period at pre-dose (fasted) on Day 1 (Hour 0) and post-dose (fed) on Day 1 at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 12.5, 13, 14, 15, 16, 18, and 24 hours.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>Analysis population included randomized participants who received study drug and had mean plasma glucose measurements during all of the specific collection time frames.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Weighted Mean Plasma Glucose</title>
          <description>Blood was collected during each treatment period at pre-dose (fasted) on Day 1 (Hour 0) and post-dose (fed) on Day 1 at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 12.5, 13, 14, 15, 16, 18, and 24 hours.</description>
          <population>Analysis population included randomized participants who received study drug and had mean plasma glucose measurements during all of the specific collection time frames.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.6" spread="26.94"/>
                    <measurement group_id="O2" value="175.7" spread="29.88"/>
                    <measurement group_id="O3" value="169.1" spread="35.91"/>
                    <measurement group_id="O4" value="170.4" spread="41.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weighted Mean Postprandial Plasma Glucose</title>
        <description>The weighted mean postprandial glucose over the specified intervals were analyzed by cohort.</description>
        <time_frame>At 0-5 hours, 5-12 hrs, and 12-18 hrs after the morning dose (up to 18 hours)</time_frame>
        <population>Analysis population included randomized participants who received assigned dose and had postprandial plasma glucose measurements during the specific time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean Postprandial Plasma Glucose</title>
          <description>The weighted mean postprandial glucose over the specified intervals were analyzed by cohort.</description>
          <population>Analysis population included randomized participants who received assigned dose and had postprandial plasma glucose measurements during the specific time frame.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.1" spread="38.27"/>
                    <measurement group_id="O2" value="187.2" spread="41.37"/>
                    <measurement group_id="O3" value="194.1" spread="46.87"/>
                    <measurement group_id="O4" value="189.9" spread="53.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 to 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.4" spread="25.76"/>
                    <measurement group_id="O2" value="159.8" spread="28.46"/>
                    <measurement group_id="O3" value="160.5" spread="42.14"/>
                    <measurement group_id="O4" value="161.5" spread="40.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to 18 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.7" spread="35.98"/>
                    <measurement group_id="O2" value="190.7" spread="35.38"/>
                    <measurement group_id="O3" value="182.6" spread="40.79"/>
                    <measurement group_id="O4" value="181.9" spread="40.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Plasma Glucose</title>
        <description>Blood samples were to be collected following a fast from all food and drink (except water) for at least 8 hours. Fasting Plasma Glucose was collected as part of the assessment of weighted mean 24-hour plasma glucose. As such, it was not specified as an endpoint in the Statistical Analysis Plan and was not analyzed or summarized separately.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>The protocol listed fasting plasma glucose as one of the endpoints of the study. However, given the assessment of weighted mean 24-hour plasma glucose and weighted mean postprandial glucose following the 3 meals on Day 1 of each period, analysis of fasting plasma glucose was not undertaken.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>Blood samples were to be collected following a fast from all food and drink (except water) for at least 8 hours. Fasting Plasma Glucose was collected as part of the assessment of weighted mean 24-hour plasma glucose. As such, it was not specified as an endpoint in the Statistical Analysis Plan and was not analyzed or summarized separately.</description>
          <population>The protocol listed fasting plasma glucose as one of the endpoints of the study. However, given the assessment of weighted mean 24-hour plasma glucose and weighted mean postprandial glucose following the 3 meals on Day 1 of each period, analysis of fasting plasma glucose was not undertaken.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting C-peptide</title>
        <description>The fasting c-peptide was analyzed by cohort using a mixed-effects model with sequence, period, and treatment as fixed effects and participant within sequence as a random effect.</description>
        <time_frame>Up to 24 hours (0 and 24 hours)</time_frame>
        <population>Analysis population included randomized participants who received assigned dose and had fasting c-peptide measurements during the specific time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting C-peptide</title>
          <description>The fasting c-peptide was analyzed by cohort using a mixed-effects model with sequence, period, and treatment as fixed effects and participant within sequence as a random effect.</description>
          <population>Analysis population included randomized participants who received assigned dose and had fasting c-peptide measurements during the specific time frame.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="1.148" lower_limit="2.54" upper_limit="3.11"/>
                    <measurement group_id="O2" value="2.76" spread="0.997" lower_limit="2.47" upper_limit="3.04"/>
                    <measurement group_id="O3" value="3.00" spread="0.916" lower_limit="2.64" upper_limit="3.35"/>
                    <measurement group_id="O4" value="2.99" spread="0.973" lower_limit="2.64" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing an Adverse Event</title>
        <description>An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug.</description>
        <time_frame>Up to 16 days</time_frame>
        <population>Analysis population includes all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event</title>
          <description>An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug.</description>
          <population>Analysis population includes all treated participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Study Drug Due to an Adverse Event</title>
        <description>An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug. Data include participants discontinued due to adverse events, participants with dose reduced or temporary discontinuation due to adverse events.</description>
        <time_frame>Up to 8 days (Day 1 in each dosing period)</time_frame>
        <population>Analysis population includes all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Drug Due to an Adverse Event</title>
          <description>An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug. Data include participants discontinued due to adverse events, participants with dose reduced or temporary discontinuation due to adverse events.</description>
          <population>Analysis population includes all treated participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin</title>
        <description>Pharmacokinetic (PK) parameter of AUClast for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
        <time_frame>0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose</time_frame>
        <population>All participants randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin</title>
          <description>Pharmacokinetic (PK) parameter of AUClast for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
          <population>All participants randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.8" spread="26"/>
                    <measurement group_id="O2" value="132.7" spread="28"/>
                    <measurement group_id="O3" value="272" spread="19"/>
                    <measurement group_id="O4" value="270.5" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Ertugliflozin</title>
        <description>PK parameter of Cmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
        <time_frame>0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose</time_frame>
        <population>All participants randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Ertugliflozin</title>
          <description>PK parameter of Cmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
          <population>All participants randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.51" spread="39"/>
                    <measurement group_id="O2" value="26.98" spread="37"/>
                    <measurement group_id="O3" value="34.80" spread="23"/>
                    <measurement group_id="O4" value="50.83" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin</title>
        <description>PK parameter of Tmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
        <time_frame>0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose</time_frame>
        <population>All participants randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
            <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
            <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
            <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
            <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin</title>
          <description>PK parameter of Tmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.</description>
          <population>All participants randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="0.500" upper_limit="12.0"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.500" upper_limit="5.50"/>
                    <measurement group_id="O3" value="6.00" lower_limit="0.500" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.500" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 16 days (including 7-day follow-up for each period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Ertugliflozin 1 mg Twice Daily</title>
          <description>Participants received ertugliflozin 1 mg twice daily for 1 day</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: Ertugliflozin 2 mg Once Daily</title>
          <description>Participants received ertugliflozin 2 mg once daily for 1 day</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: Ertugliflozin 2 mg Twice Daily</title>
          <description>Participants received ertugliflozin 2 mg twice daily for 1 day</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2: Ertugliflozin 4 mg Once Daily</title>
          <description>Participants received ertugliflozin 4 mg once daily for 1 day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to Pfizer at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Institution agrees to delay the disclosure for a period not to exceed an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

